CASI Pharmaceuticals Secures $20 Million for Renal AMR Study

The latest announcement is out from CASI Pharmaceuticals ( (CASI) ).

On December 11, 2025, CASI Pharmaceuticals announced a $20 million convertible note financing agreement with ETP Global III Fund LP to support a Phase 1 study in China for renal allograft antibody-mediated rejection (AMR). This investment, structured in tranches, will also aid in developing a stable, high concentration protein solution for subcutaneous formulation, potentially enhancing CASI’s market position in biopharmaceuticals. The financing reflects strategic growth efforts, although it involves risks such as market volatility and operational challenges.

The most recent analyst rating on (CASI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.

Spark’s Take on CASI Stock

According to Spark, TipRanks’ AI Analyst, CASI is a Underperform.

CASI Pharmaceuticals has a low overall stock score due to significant financial challenges, including declining revenue and increasing losses, coupled with bearish technical indicators and poor valuation metrics. The absence of positive earnings call data or corporate events further weighs on the score.

To see Spark’s full report on CASI stock, click here.

More about CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focusing on the development of CID-103, an anti-CD38 monoclonal antibody, for treating organ transplant rejection and autoimmune diseases. The company holds exclusive global rights to CID-103 and is actively engaged in clinical trials, including a Phase 1 study in renal allograft antibody-mediated rejection (AMR) in the U.S. and immune thrombocytopenia (ITP).

Average Trading Volume: 120,251

Technical Sentiment Signal: Sell

Current Market Cap: $13.28M

Learn more about CASI stock on TipRanks’ Stock Analysis page.